LAPSTriple Agonist, an innovative triple-acting new drug for NASH treatment, indication expansion
Efpeglenatide met the primary endpoint for global Phase 3
Striving for developing rare diseases such as a once-a-month drug for short-bowel syndrome
SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.
What will be Hanmi s 2021 R&D strategy on new drugs
Se Chang Kwon, the CEO of Hanmi Pharmaceutical Co., Ltd., is presenting the vision and strategy of Hanmi Pharmaceutical Co., Ltd. in 2021 at the 39th JP Morgan Conference.
Hanmi presenta el paquete de soluciones para combatir la COVID-19
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Börse Express - Hanmi präsentiert Lösungspaket zur Bewältigung von COVID-19, einschließlich der Massenproduktion von Nukleinsäure-Impfstoffen (DNA
boerse-express.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boerse-express.com Daily Mail and Mail on Sunday newspapers.